<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://new.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Tue, 20 Oct 2026 07:02:11 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://new.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Sophia Learning and National University partner on credit transfer program</title>
   <link>http://www.streetinsider.com/Corporate+News/Sophia+Learning+and+National+University+partner+on+credit+transfer+program/27206436.html</link>
   <description>

&lt;p&gt;Sophia Learning, an online self-paced learning platform and subsidiary of Strategic Education, Inc., announced a partnership with National University (NU), a nonprofit university, that will allow eligible NU undergraduates to transfer courses completed through the Sophia platform toward eligible NU degree programs.&lt;/p&gt;

&lt;p&gt;Sophia Learning offers more than 80 courses recommended for college-level credit by the American Council on Education (ACE), available through a monthly subscription. The arrangement is intended to give NU students a way to complete general education requirements at a lower cost.&lt;/p&gt;

&lt;p&gt;&quot;National University is focused on expanding access to high-quality education and supporting students at every stage of their</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/Sophia+Learning+and+National+University+partner+on+credit+transfer+program/27206436.html</guid>
   <pubDate>Tue, 20 Oct 2026 07:02:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Sophia Learning and National University Announce Partnership to Expand Affordable Pathways to Degree Completion</title>
   <link>http://www.streetinsider.com/Press+Releases/Sophia+Learning+and+National+University+Announce+Partnership+to+Expand+Affordable+Pathways+to+Degree+Completion/27206431.html</link>
   <description>
&lt;p&gt;    HERNDON, Va.--(BUSINESS WIRE)--
Sophia Learning, an online, on-demand, self-paced learning platform offering courses recommended for college-level credit by ACE®, today announced a new partnership with National University (NU), a nonprofit, Veteran-founded university focused on flexible degree pathways for learners balancing work, life, and education. The partnership will allow eligible NU undergraduates to transfer courses taken through the Sophia platform towards eligible NU programs.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20261014502114/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20261014502114/en/&lt;/a&gt;&lt;/p&gt;&lt;p&gt;
&quot;National University is focused on expanding access to high-quality education and supporting students at every stage of their learning journey,&quot; said</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Sophia+Learning+and+National+University+Announce+Partnership+to+Expand+Affordable+Pathways+to+Degree+Completion/27206431.html</guid>
   <pubDate>Tue, 20 Oct 2026 07:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Sophia Learning and National University Announce Partnership to Expand Affordable Pathways to Degree Completion</title>
   <link>http://www.streetinsider.com/Business+Wire/Sophia+Learning+and+National+University+Announce+Partnership+to+Expand+Affordable+Pathways+to+Degree+Completion/27206431.html</link>
   <description>
&lt;p&gt;    HERNDON, Va.--(BUSINESS WIRE)--
Sophia Learning, an online, on-demand, self-paced learning platform offering courses recommended for college-level credit by ACE®, today announced a new partnership with National University (NU), a nonprofit, Veteran-founded university focused on flexible degree pathways for learners balancing work, life, and education. The partnership will allow eligible NU undergraduates to transfer courses taken through the Sophia platform towards eligible NU programs.

&lt;/p&gt;&lt;p id=&quot;news-body-cta&quot;&gt;This press release features multimedia. View the full release here: &lt;a target=&quot;_blank&quot; href=&quot;https://www.businesswire.com/news/home/20261014502114/en/&quot; rel=&quot;nofollow&quot;&gt;https://www.businesswire.com/news/home/20261014502114/en/&lt;/a&gt;&lt;/p&gt;&lt;p&gt;
&quot;National University is focused on expanding access to high-quality education and supporting students at every stage of their learning journey,&quot; said</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Sophia+Learning+and+National+University+Announce+Partnership+to+Expand+Affordable+Pathways+to+Degree+Completion/27206431.html</guid>
   <pubDate>Tue, 20 Oct 2026 07:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>BMO: 'We view the readthrough as modestly positive for CVSA/STRA'</title>
   <link>http://www.streetinsider.com/Analyst+Comments/BMO%3A+%27We+view+the+readthrough+as+modestly+positive+for+CVSASTRA%27/27196575.html</link>
   <description>&lt;p&gt;BMO: 'We view the readthrough as modestly positive for CVSA/STRA'.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;The recently released updated PEER Center analysis of ED earnings data points to lower estimated regulatory exposure than the December 2025 data we previously analyzed. CVSA and STRA show the most notable improvement as large mental/social health master’s programs moved to passing. PXED again has no failing programs, while LOPE’s single failure is unchanged and misses the threshold by just 0.2%. We view the readthrough as modestly positive for CVSA/STRA, with little incremental change for LOPE/PXED. While for-profit fail rate data is concerning (30%), our covered companies screen</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/BMO%3A+%27We+view+the+readthrough+as+modestly+positive+for+CVSASTRA%27/27196575.html</guid>
   <pubDate>Fri, 16 Oct 2026 10:05:47 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVSA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LOPE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PXED</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>BMO: 'We view the readthrough as modestly positive for CVSA/STRA'</title>
   <link>http://www.streetinsider.com/Analyst+Comments/BMO%3A+%27We+view+the+readthrough+as+modestly+positive+for+CVSASTRA%27/27196575.html</link>
   <description>&lt;p&gt;BMO: 'We view the readthrough as modestly positive for CVSA/STRA'.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;The recently released updated PEER Center analysis of ED earnings data points to lower estimated regulatory exposure than the December 2025 data we previously analyzed. CVSA and STRA show the most notable improvement as large mental/social health master’s programs moved to passing. PXED again has no failing programs, while LOPE’s single failure is unchanged and misses the threshold by just 0.2%. We view the readthrough as modestly positive for CVSA/STRA, with little incremental change for LOPE/PXED. While for-profit fail rate data is concerning (30%), our covered companies screen</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/BMO%3A+%27We+view+the+readthrough+as+modestly+positive+for+CVSASTRA%27/27196575.html</guid>
   <pubDate>Fri, 16 Oct 2026 10:05:47 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVSA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LOPE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PXED</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>BMO: 'We view the readthrough as modestly positive for CVSA/STRA'</title>
   <link>http://www.streetinsider.com/Analyst+Comments/BMO%3A+%27We+view+the+readthrough+as+modestly+positive+for+CVSASTRA%27/27196575.html</link>
   <description>&lt;p&gt;BMO: 'We view the readthrough as modestly positive for CVSA/STRA'.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;The recently released updated PEER Center analysis of ED earnings data points to lower estimated regulatory exposure than the December 2025 data we previously analyzed. CVSA and STRA show the most notable improvement as large mental/social health master’s programs moved to passing. PXED again has no failing programs, while LOPE’s single failure is unchanged and misses the threshold by just 0.2%. We view the readthrough as modestly positive for CVSA/STRA, with little incremental change for LOPE/PXED. While for-profit fail rate data is concerning (30%), our covered companies screen</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/BMO%3A+%27We+view+the+readthrough+as+modestly+positive+for+CVSASTRA%27/27196575.html</guid>
   <pubDate>Fri, 16 Oct 2026 10:05:47 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVSA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LOPE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PXED</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>BMO: 'We view the readthrough as modestly positive for CVSA/STRA'</title>
   <link>http://www.streetinsider.com/Analyst+Comments/BMO%3A+%27We+view+the+readthrough+as+modestly+positive+for+CVSASTRA%27/27196575.html</link>
   <description>&lt;p&gt;BMO: 'We view the readthrough as modestly positive for CVSA/STRA'.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;The recently released updated PEER Center analysis of ED earnings data points to lower estimated regulatory exposure than the December 2025 data we previously analyzed. CVSA and STRA show the most notable improvement as large mental/social health master’s programs moved to passing. PXED again has no failing programs, while LOPE’s single failure is unchanged and misses the threshold by just 0.2%. We view the readthrough as modestly positive for CVSA/STRA, with little incremental change for LOPE/PXED. While for-profit fail rate data is concerning (30%), our covered companies screen</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/BMO%3A+%27We+view+the+readthrough+as+modestly+positive+for+CVSASTRA%27/27196575.html</guid>
   <pubDate>Fri, 16 Oct 2026 10:05:47 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVSA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LOPE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PXED</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Form  SCHEDULE 13G/A  Strategic Education,                   Filed by: DIMENSIONAL FUND ADVISORS LP</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Strategic+Education%2C+++++++++++++++++++Filed+by%3A+DIMENSIONAL+FUND+ADVISORS+LP/27166495.html</link>
   <description>si-local-file:///var/storage/secattach/20261008/27166495.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Strategic+Education%2C+++++++++++++++++++Filed+by%3A+DIMENSIONAL+FUND+ADVISORS+LP/27166495.html</guid>
   <pubDate>Thu, 08 Oct 2026 14:26:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Strategic Education (STRA) PT Lowered to $95 at BMO Capital</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Strategic+Education+%28STRA%29+PT+Lowered+to+%2495+at+BMO+Capital/27145624.html</link>
   <description>BMO Capital analyst Jeffrey Silber lowered the price target on Strategic Education (NASDAQ: STRA) to $95.00  (from $100.00) while maintaining a Outperform rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Strategic+Education+%28STRA%29+PT+Lowered+to+%2495+at+BMO+Capital/27145624.html</guid>
   <pubDate>Mon, 05 Oct 2026 07:20:48 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Strategic Education, Inc. Schedules Third Quarter 2026 Results Conference Call</title>
   <link>http://www.streetinsider.com/Press+Releases/Strategic+Education%2C+Inc.+Schedules+Third+Quarter+2026+Results+Conference+Call/27128634.html</link>
   <description>
&lt;p&gt;    HERNDON, Va.--(BUSINESS WIRE)--
Strategic Education, Inc. (Strategic Education) (NASDAQ: STRA) today announced that it will host a conference call to discuss its third quarter results on Thursday, November 5, 2026 at 10:00 a.m. ET. A news release outlining the results will be issued before the market opens the same day.

&lt;/p&gt;&lt;p&gt;
This call will be available via webcast. To access the live webcast of the conference call on November 5, please go to &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.strategiceducation.com&amp;amp;esheet=54613578&amp;amp;newsitemid=20260930416974&amp;amp;lan=en-US&amp;amp;anchor=www.strategiceducation.com&amp;amp;index=1&amp;amp;md5=877786573d20960c101e8a3ce2afef6f&quot; shape=&quot;rect&quot;&gt;www.strategiceducation.com&lt;/a&gt; in the &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.strategiceducation.com%2Finvestor-relations%2Foverview%2Fdefault.aspx&amp;amp;esheet=54613578&amp;amp;newsitemid=20260930416974&amp;amp;lan=en-US&amp;amp;anchor=Investor+Relations&amp;amp;index=2&amp;amp;md5=e0f853004387a2dda3821d4be953c886&quot; shape=&quot;rect&quot;&gt;Investor Relations&lt;/a&gt; section 15 minutes prior to the start time of the call to register.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Strategic+Education%2C+Inc.+Schedules+Third+Quarter+2026+Results+Conference+Call/27128634.html</guid>
   <pubDate>Wed, 30 Sep 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Strategic Education, Inc. Schedules Third Quarter 2026 Results Conference Call</title>
   <link>http://www.streetinsider.com/Business+Wire/Strategic+Education%2C+Inc.+Schedules+Third+Quarter+2026+Results+Conference+Call/27128634.html</link>
   <description>
&lt;p&gt;    HERNDON, Va.--(BUSINESS WIRE)--
Strategic Education, Inc. (Strategic Education) (NASDAQ: STRA) today announced that it will host a conference call to discuss its third quarter results on Thursday, November 5, 2026 at 10:00 a.m. ET. A news release outlining the results will be issued before the market opens the same day.

&lt;/p&gt;&lt;p&gt;
This call will be available via webcast. To access the live webcast of the conference call on November 5, please go to &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.strategiceducation.com&amp;amp;esheet=54613578&amp;amp;newsitemid=20260930416974&amp;amp;lan=en-US&amp;amp;anchor=www.strategiceducation.com&amp;amp;index=1&amp;amp;md5=877786573d20960c101e8a3ce2afef6f&quot; shape=&quot;rect&quot;&gt;www.strategiceducation.com&lt;/a&gt; in the &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.strategiceducation.com%2Finvestor-relations%2Foverview%2Fdefault.aspx&amp;amp;esheet=54613578&amp;amp;newsitemid=20260930416974&amp;amp;lan=en-US&amp;amp;anchor=Investor+Relations&amp;amp;index=2&amp;amp;md5=e0f853004387a2dda3821d4be953c886&quot; shape=&quot;rect&quot;&gt;Investor Relations&lt;/a&gt; section 15 minutes prior to the start time of the call to register.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Strategic+Education%2C+Inc.+Schedules+Third+Quarter+2026+Results+Conference+Call/27128634.html</guid>
   <pubDate>Wed, 30 Sep 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Harris Poll: 70% of Gen Z Healthcare Workers Look to Leave as U.S. Faces Critical Healthcare Workforce Shortage, Commissioned by Workforce Edge</title>
   <link>http://www.streetinsider.com/Press+Releases/Harris+Poll%3A+70%25+of+Gen+Z+Healthcare+Workers+Look+to+Leave+as+U.S.+Faces+Critical+Healthcare+Workforce+Shortage%2C+Commissioned+by+Workforce+Edge/27067310.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Survey reveals expectations of younger employees; declining interest in AI among employers&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    HERNDON, Va.--(BUSINESS WIRE)--
One year after the initial survey, the &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fworkforceedge.com%2Fhealthcare-workforce-barometer%3Futm_id%3Dsei238%26utm_source%3Dpartner%26utm_medium%3Dweb%26utm_campaign%3Dhealthc&amp;amp;esheet=54604967&amp;amp;newsitemid=20260916296354&amp;amp;lan=en-US&amp;amp;anchor=2026+Healthcare+Workforce+Barometer&amp;amp;index=1&amp;amp;md5=6f9d8f23c55a84ad15024133ae7e5b7c&quot; shape=&quot;rect&quot;&gt;2026 Healthcare Workforce Barometer&lt;/a&gt; conducted by The Harris Poll finds that more than half of the healthcare workforce (59%) is still looking to leave with 70% of Gen Z healthcare workers saying they will look for a new role in the next year. These findings come as the U.S. is projected to face a shortage of nearly 500,000 critical healthcare workers by 2038 &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fdata.hrsa.gov%2Ftopics%2Fhealth-workforce%2Fnchwa%2Fworkforce-projections&amp;amp;esheet=54604967&amp;amp;newsitemid=20260916296354&amp;amp;lan=en-US&amp;amp;anchor=%28HRSA%2C+2025%29&amp;amp;index=2&amp;amp;md5=929e6dc6caa3720d3aaf751766c84e9a&quot; shape=&quot;rect&quot;&gt;(HRSA, 2025)&lt;/a&gt;.

&lt;/p&gt;&lt;p&gt;
Strategic Education, Inc.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Harris+Poll%3A+70%25+of+Gen+Z+Healthcare+Workers+Look+to+Leave+as+U.S.+Faces+Critical+Healthcare+Workforce+Shortage%2C+Commissioned+by+Workforce+Edge/27067310.html</guid>
   <pubDate>Wed, 16 Sep 2026 07:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Harris Poll: 70% of Gen Z Healthcare Workers Look to Leave as U.S. Faces Critical Healthcare Workforce Shortage, Commissioned by Workforce Edge</title>
   <link>http://www.streetinsider.com/Business+Wire/Harris+Poll%3A+70%25+of+Gen+Z+Healthcare+Workers+Look+to+Leave+as+U.S.+Faces+Critical+Healthcare+Workforce+Shortage%2C+Commissioned+by+Workforce+Edge/27067310.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Survey reveals expectations of younger employees; declining interest in AI among employers&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    HERNDON, Va.--(BUSINESS WIRE)--
One year after the initial survey, the &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fworkforceedge.com%2Fhealthcare-workforce-barometer%3Futm_id%3Dsei238%26utm_source%3Dpartner%26utm_medium%3Dweb%26utm_campaign%3Dhealthc&amp;amp;esheet=54604967&amp;amp;newsitemid=20260916296354&amp;amp;lan=en-US&amp;amp;anchor=2026+Healthcare+Workforce+Barometer&amp;amp;index=1&amp;amp;md5=6f9d8f23c55a84ad15024133ae7e5b7c&quot; shape=&quot;rect&quot;&gt;2026 Healthcare Workforce Barometer&lt;/a&gt; conducted by The Harris Poll finds that more than half of the healthcare workforce (59%) is still looking to leave with 70% of Gen Z healthcare workers saying they will look for a new role in the next year. These findings come as the U.S. is projected to face a shortage of nearly 500,000 critical healthcare workers by 2038 &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fdata.hrsa.gov%2Ftopics%2Fhealth-workforce%2Fnchwa%2Fworkforce-projections&amp;amp;esheet=54604967&amp;amp;newsitemid=20260916296354&amp;amp;lan=en-US&amp;amp;anchor=%28HRSA%2C+2025%29&amp;amp;index=2&amp;amp;md5=929e6dc6caa3720d3aaf751766c84e9a&quot; shape=&quot;rect&quot;&gt;(HRSA, 2025)&lt;/a&gt;.

&lt;/p&gt;&lt;p&gt;
Strategic Education, Inc.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Harris+Poll%3A+70%25+of+Gen+Z+Healthcare+Workers+Look+to+Leave+as+U.S.+Faces+Critical+Healthcare+Workforce+Shortage%2C+Commissioned+by+Workforce+Edge/27067310.html</guid>
   <pubDate>Wed, 16 Sep 2026 07:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
  <item>
   <title>Capella University names oncologist Dr. Saro Sarkisian to board</title>
   <link>http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</link>
   <description>

&lt;p&gt;Capella University has appointed Saro Sarkisian, MD, MHA, to its Board of Trustees, according to a statement from the Minneapolis-based online university.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian is a board-certified medical oncologist and hematologist who currently serves as Clinical Director of Cellular Therapeutics at Frederick Health and practices at the James M. Stockman Cancer Institute in Frederick, Maryland. He has served as a lead oncologist in clinical settings and as a principal investigator on national and international clinical trials.&lt;/p&gt;

&lt;p&gt;Dr. Sarkisian has advised on the development of immuno-oncology therapeutics, including antibody-drug conjugates and monoclonal antibodies, and has contributed to the expansion of oncology access in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Capella+University+names+oncologist+Dr.+Saro+Sarkisian+to+board/26952647.html</guid>
   <pubDate>Thu, 20 Aug 2026 07:01:11 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.17409901</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.32437804</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.35954321</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.41389538</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00162576</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01913171</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01982880</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20737027</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.41713299</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">STRA</category>
   	  </item>
 </channel>
</rss>
